The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase Ib study of CNTO 888 (anti-CCL 2) in combination with chemotherapies for treatment of patients with solid tumors.
Antonio Calles
No relevant relationships to disclose
Irene Brana
No relevant relationships to disclose
Patricia LoRusso
Research Funding - Centocor Ortho Biotech
Lorrin Yee
No relevant relationships to disclose
Thomas Puchalski
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Shobha Seetharam
Employment or Leadership Position - Janssen Pharmaceutical
Stock Ownership - Johnson & Johnson
Melan Balvers
Employment or Leadership Position - Janssen Bioloigcs BV
Carla De Boer
Employment or Leadership Position - Janssen Pharmaceutical
Yusri A. Elsayed
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Emiliano Calvo
Research Funding - Janssen-Cilag
Josep Tabernero
Consultant or Advisory Role - Janssen-Cilag; Johnson & Johnson